<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov:80/entrez/query/static/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>Science and Education Publishing</PublisherName>
<JournalTitle>Journal of Food and Nutrition Research</JournalTitle>
<Issn>2333-1240</Issn>
<Volume>4</Volume>
<Issue>8</Issue>
<PubDate PubStatus="epublish">
<Year>2016</Year>
<Month>8</Month>
<Day>19</Day>
</PubDate>
</Journal>
<ArticleTitle>Silibinin Suppresses Mediators of Inflammation through the Inhibition of TLR4-TAK1 Pathway in LPS-induced RAW264.7 Cells</ArticleTitle>
<FirstPage>515</FirstPage>
<LastPage>521</LastPage>
<Language>EN</Language>
<AuthorList>
<Author>
<FirstName>Ji-Hyeon</FirstName>
<LastName>Song</LastName>
</Author>
<Author>
<FirstName>Kui-Jin</FirstName>
<LastName>Kim</LastName>
</Author>
<Author>
<FirstName>Boo-Yong</FirstName>
<LastName>Lee</LastName>
<Affiliation>Department of Food Science and Biotechnology, CHA University, Kyonggi 463-400, South Korea</Affiliation>
</Author>

</AuthorList>
<ArticleIdList>
<ArticleId IdType="pii">JFNR2016485</ArticleId>
<ArticleId IdType="doi">10.12691/jfnr-4-8-5</ArticleId>
</ArticleIdList>
<History>
<PubDate PubStatus="received">
<Year>2016</Year>
<Month>4</Month>
<Day>27</Day>
</PubDate>
<PubDate PubStatus="revised">
<Year>2016</Year>
<Month>6</Month>
<Day>10</Day>
</PubDate>
<PubDate PubStatus="accepted">
<Year>2016</Year>
<Month>8</Month>
<Day>17</Day>
</PubDate>
</History>
<Abstract>Silibinin is the major bioactive compound of silymarin which is the mixture of flavonolignans extracted from milk thistle. Silibinin has been shown to possess anti-inflammatory activity. However, the underlying mechanisms still remain unclear. The aims of this study were to determine the effect of silibinin on molecular mechanism in lipopolysaccharide (LPS)-induced RAW264.7 macrophage cells. Here, we observed that silibinin attenuated the production of nitric oxide (NO) and its regulatory protein inducible nitric oxide synthase (iNOS) expression. The pro-inflammatory cytokine interleukin (IL)-1β was inhibited by silibinin in a time dependent manner. Moreover, silibinin decreased the expression of toll-like receptor (TLR)-4, TAK1, and IRF3. TLR- associated MAPK signaling pathway was also dramatically down-regulated in LPS-induced RAW 264.7 cells with presence of silibinin. Silibinin repressed oxidative stress-associated proteins including NOX4, G6PDH, and CuZnSOD, while silibinin increased the expression of GR and catalase in LPS-induced RAW264.7 cells. In the current study, silibinin suppresses the LPS-induced inflammation via modulation of TLR4-TAK1 signaling and subsequently attenuated the production of inflammation mediators in RAW264.7 cells. Therefore, we suggest that silibinin has a potential bioactivity for prevention and intervention of endotoxin-mediated inflammation and TLR4-TAK1-associated chronic diseases.</Abstract>
</Article>
</ArticleSet>
